Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

[1]  C. Bailey,et al.  Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP , 2002, Diabetologia.

[2]  M. Nauck,et al.  Gastric Inhibitory Polypeptide: the neglected incretin revisited , 2002, Regulatory Peptides.

[3]  J. Holst,et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.

[4]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[5]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[6]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[7]  M. Nauck,et al.  Gut hormones and diabetes mellitus. , 1992, Diabetes/metabolism reviews.

[8]  T. McDonald,et al.  Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia. , 1991, The Journal of clinical endocrinology and metabolism.

[9]  J. Holst.  Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. , 1982, The Biochemical journal.

[10]  J. Brown,et al.  Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. , 1978, Endocrinology.